ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1654616
This article is part of the Research TopicThe Role of Immunotherapy in Cancer Therapy and Its ChallengeView all 3 articles
PD-1 Inhibitor Combined with TPF Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Study of Efficacy and Safety
Provisionally accepted
- 1Chengdu Fifth People's Hospital, Chengdu, China
- 2Chengdu University of Traditional Chinese Medicine, Chengdu, China
- 3The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Background: The efficacy of PD-1 inhibitors in the induction therapy of locally advanced nasopharyngeal carcinoma (LA-NPC) remains unclear. The aim of this study was to retrospectively investigate the efficacy and safety of PD-1 inhibitor combined with induction chemotherapy in patients with LA-NPC. Patients and Methods: A retrospective study was conducted on 158 LA-NPC patients, 80 patients received TPF (nab-paclitaxel, cisplatin and 5-fuorouracil) induction chemotherapy, and 78 patients received TPF-ICB (TPF plus PD-1 inhibitor) chemoimmunotherapy. Treatment response was evaluated immediately following completion of induction therapy using RECIST v1.1 criteria, including cervical lymph nodes and primary nasopharynx lesions. Responses were categorized as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD), with objective response rate (ORR) calculated as the combined CR+PR rate. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and toxicity assessment. Acute treatment-related toxicities during induction therapy were graded according to CTCAE v5.0 criteria and compared between treatment groups. Results: After induction therapy, the ORR in the TPF group was significantly lower than that in the TPF-ICB group (71.2% vs. 88.5%, p = 0.007). The complete response (CR) rate in the TPF-ICB group was significantly higher than in the TPF group (29.5% vs. 11.3%，p = 0.007). The 3 and 5 years PFS rates in TPF-ICB group were 99% and 95%, which were significantly higher than the TPF group (89% and 87%, both p ＜ 0.05). The 3-year (99% vs. 89%, p ＜0.001) and 5-years OS rates (95% vs. 87%, p ＜ 0.0001) were superior in the TPF-ICB group. Grade ≥3 TRAEs occurred in 7 (8.6%) and 12 (15.5%) patients in the TPF and TPF-ICB groups, respectively (p = 0.596). Conclusions: The induction therapy of PD-1 inhibitor combined with TPF showed high CR and ORR rates in LA-NPC, and the safety was acceptable. Keywords: Locally advanced stage nasopharyngeal, TPF, PD-1 inhibitor, concurrent chemoradiotherapy, efficacy and safety
Keywords: Locally advanced stage nasopharyngeal, TPF, PD-1 inhibitor, concurrent chemoradiotherapy, efficacy and safety
Received: 26 Jun 2025; Accepted: 27 Aug 2025.
Copyright: © 2025 Zhang, Meng, Zhang, Tian, Zeng, DONG and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Weiwei Zhang, Chengdu Fifth People's Hospital, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.